放化疗联合唑来膦酸治疗肺癌骨转移临床观察.docVIP

放化疗联合唑来膦酸治疗肺癌骨转移临床观察【中图分类号】R734.2 【文献标识码】 A 【文章编号】1672-3873（2011）03-0361-02 【摘要】目的：观察放化疗联合唑来膦酸治疗肺癌骨转移癌疼痛的疗效及对生存质量的影响。方法：分析我院2007年1月―2010年5月收治的54例采用放化疗联合唑来膦酸治疗肺癌骨转移患者的临床及随访资料。患者均接受了局部骨转移灶30Gy/10fx放疗，4周期联合铂类药物方案的化疗及2周期唑来膦酸治疗。结果：疼痛缓解率：完全缓解（CR）：48#8226;15% (26/54)，部分缓解（PR）35#8226;19% (19/54)，轻度缓解（MR）：9#8226;26% (5/54)，无效（NR）：7#8226;41% (4/54)，总有效率(CR+PR)为83#8226;33% (45/54)。骨转移灶控制率：完全缓解(CR)：11#8226;11% (6/54)，PR（部分缓解）：31#8226;48% （17/54），NC（无效）： 38#8226;89%（21/54），PD（进展）： 20#8226;37% （11/54）总有效率（CR+PR）为42#8226;60%（23/54）。治疗结束后2个月活动能力改善情况：显效：29#8226;63%（16/54），有效：59#8226;26%（32/54），无效：11#8226;11%（6/54），总有效率：88#8226;89%（48/54）。结论：放化疗联合唑来膦酸是治疗乳腺癌骨转移的一较为理想的治疗方案。 【关键词】肺癌/骨转移;放化疗/唑莱膦酸;疼痛缓解率 Clinical observation of chemoradiotherapy combined with zoledronic acid for the patients with bone metastasis in lung cancer NI Yu-feng，LIAO Zhi-jun，Department of Oncolog,Chong ming Center Hospital,Shanghai 202150,China 【Abstract】Objective: To observe the effects and the influence on life quality of chemoradiotherapy combined with zoledronic acid in the treatment of bone metastasis of lung cancer.Methods:From Jan 2007 to May 2010, 54 patients with bone metastasis in lung cancer were analyzed#8226;All patients were given radiotherap(30Gy/10fx) for local bone metastases, and 4 cycle platinum-based chemotherapy and 2 cycle zoledronic acid.Results:The pain relief rate:complete response (CR)was48#8226;15% (26/54), partial response (PR)was35#8226;19% (19/54),minor response(MR)was9#8226;26% (5/54) and no response(NR)was 7#8226;41% (4/54); Control rates of bone metastases: the overall response was 42#8226;60%, CR was 11#8226;11% (6/54), PR was 31#8226;48%(17/54) and NC was 42#8226;60% (23/54), development(PD) was 20#8226;37% (11/54);Activities improve after ending the treatment in 2 months:the overall responsewas 88#8226;89% (48/54) and CR was 16 case(29#8226;63% ), PR was 32 cases(59#8226;26% ) and NR was 6 cases (11#8226;11% ).Conclusions:Chemoradiotherapy combined with zoledronic